AKT1 and non-small cell lung carcinoma: These data suggested that the increased Akt and ERK activities in response to CSE and B[α]P treatment may result from an alternative signaling and thereby contribute to the insensitivity of wtEGFR‐expressing smoker NSCLC patients to EGFR TKIs.